Brain and Nervous System, Cancer
Conditions
Keywords
Phase I, Brain cancer, Recurrent CNS tumors
Brief summary
The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2. How well does this combination work to shrink brain tumors, and how long do responses to treatment last? 3. What side effects does the combination of drugs cause? 4. How does treatment affect patients' quality of life (how they feel and what activities they are able to do)?
Detailed description
This is a Phase I study, which means these trials are generally comparatively small and are used to determine toxicity and maximum dose. Currently, there are no standard treatments for Recurrent CNS Tumors. In this study, approximately 14 patients with Recurrent CNS Tumors will receive treatment with irinotecan, an intravenous drug, and thalidomide, a drug taken by mouth. Both have been approved by the Federal Food and Drug Administration as treatments for cancer, but they have not been tested together for brain cancer. The study will try to answer these questions: 1. What is the highest dose of thalidomide brain cancer patients can receive safely in combination with irinotecan? 2. How well does this combination work to shrink brain tumors, and how long do responses to treatment last? 3. What side effects does the combination of drugs cause? 4. How does treatment affect patients' quality of life (how they feel and what activities they are able to do)?
Interventions
DRUGIrinotecan
Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
DRUGThalidomide
Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
Sponsors
University of New Mexico
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Biopsy proven high grade astrocytomas, glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, mixed oligodendroglioma. * Subjects are allowed to have definitive surgery and/or radiation treatment to their tumors. * Subjects are allowed to have previous chemotherapy for their tumors. * Subjects who previous diagnosed to have a low grade lesion need a second biopsy to show transformation into a high grade histology. * Subjects need to have radiographic or biopsy proven recurrent disease. * ECORT performance status 2 or lower. See appendix I. * Baseline laboratory values within 30 days of study entry: hemoglobin 10 gm/dl; absolute neutrophil count 1,500 cells/ml; platelet counts 100,000 cells/ml; SGOT/AST, SGPT/ALT, alkaline phosphatase, LDH 3high normal limit; total bilirubin 2.0 mg/dl. * Ability to provide written informed consent. * Age \> 18 years. * Female patients of childbearing potential must have a documented negative serum pregnancy test within 14 days of study entry. * All subjects must agree to use an effective method of contraception for the duration of treatment if engaged in sexual activity where conception is possible, as specified in the STEP program for thalidomide.
Exclusion criteria
* Therapy with any investigational drug (other than drugs available on treatment IND and used for FDA-sanctioned indications) and/or any chemotherapy regimen within 28 days of study entry. * Prior therapy with either irinotecan or thalidomide. * Oxygen saturation 90% on room air. * Cardiac insufficiency at New York Heart Association status 2 or greater. * Other active malignancies except basal or squamous cell carcinoma of the skin or in situ cervical and breast lesions. * History of neuropsychiatric disorder or altered mental status which prevent informed consent or compliance with protocol requirement. * Known hypersensitivity or allergic reaction to study drug. * Women at any stage of pregnancy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tolerable dosage of thalidomide in combination with irinotecan | Unacceptable toxicities |
Secondary
| Measure | Time frame |
|---|---|
| Tumor response. For this study, the definition of response will include complete response, partial response and stable disease. Duration of tumor response. uality of life while on treatment | unacceptable toxicities |
Countries
United States
Outcome results
None listed